Navigation Links
Scientists find new way to fight malaria drug resistance
Date:4/17/2014

An anti-malarial treatment that lost its status as the leading weapon against the deadly disease could be given a new lease of life, with new research indicating it simply needs to be administered differently.

The findings could revive the use of the cheap anti-malarial drug chloroquine in treating and preventing the mosquito-bourne disease, which claims the lives of more than half a million people each year around the world.

The parasite that causes malaria has developed resistance to chloroquine, but research carried out at the Australian National University (ANU) and Germany's University of Heidelberg has shown that the parasite protein that causes resistance has an Achilles' heel.

"We studied diverse versions of this protein and in all cases found that it is limited in its capacity to remove the drug from the parasite," said malaria researcher Dr Rowena Martin, from the ANU Research School of Biology.

"This means malaria could once again be treated with chloroquine if it is administered twice-daily, rather than just once a day".

Once hailed as a wonder drug, chloroquine is still used in developing nations in the South Pacific, Africa, Asia and South America, but has been withdrawn from use in many developed countries.

Dr Martin and her colleagues also revealed how the protein may have developed resistance to chloroquine.

"We found that the protein gains the ability to move chloroquine out of the parasite through one of two evolutionary pathways, but that this process is rigid one wrong turn and the protein is rendered useless," she said.

"This indicates that the protein is under conflicting pressures, which is a weakness that could be exploited in future antimalarial strategies."

Dr Martin said the findings, published in the latest Proceedings of the National Academy of Sciences of the United States of America, could be used to help millions of people in developing nati
'/>"/>

Contact: ANU Media Office
media@anu.edu.au
026-125-7979
Australian National University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Stanford scientists develop playbook for reverse engineering tissue
2. Scientists unlock secrets of protein produced by disease-causing fungus
3. Kessler Foundation scientists receive Biogen Idec grant to study actual reality in MS
4. Scientists discover a number of novel genetic defects which cause oesophageal cancer
5. Scientists find potential target for treating mitochondrial disorders
6. Scientists describe gut bacteria that cause sepsis in preterm infants
7. Virginia Tech scientists out for blood when it comes to stopping malaria
8. U-M scientists slow development of Alzheimers trademark cell-killing plaques
9. NIH scientists track evolution of a superbug
10. In the lab, scientists coax E. coli to resist radiation damage
11. Let there be tissue-penetrating light: Scientists develop new nanoscale method to fight cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... tort litigation currently underway in Pennsylvania’s Philadelphia Court of ... December 24, 2014, court documents indicate that 1,183 claims ... individuals who developed gynecomastia (male breast growth) and other ... Court indicates that this represents an increase of more ...
(Date:12/24/2014)... Dallas, TX (PRWEB) December 24, 2014 ... has announced the expansion of his practice and med-spa ... to the practice’s growing list of cosmetic treatments and ... a solution into the skin,” says Dr. Ho. “As ... aging changes such as wrinkles, sun spots, discolorations or ...
(Date:12/24/2014)... the famous women’s dress supplier, has presented its new selection ... gown promotion. , For those who prefer to ... the collection should be a great choice. The dresses from ... are available with custom service. , Now, all the wedding ... 75% off; most of them come in hot designs. In ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... which is used in the treatment of colon or ... also prescribed to patients who suffer from advanced gastrointestinal ... a multi-kinase inhibitor and it blocks many enzymes which ...
(Date:12/24/2014)... 2014 BambooIndustry.com a famous bamboo flooring ... Today, the company announces its multiple layer bamboo ... on these new products. , Bamboo panel is the ... multiple layer bamboo panel board features high quality selective ... emissions free. The bamboo panel consists of multiple layers ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2
... Homegrown pharma major Panacea Biotec today said it is ... and Japanese encephalitis. // ,"We are currently ... and hepatitis-A. Phase I and II trials for anthrax ... approvals," Panacea Biotec Joint Managing Director Rajesh Jain told ...
... or lesions, that typically precede cervical cancer is much ... human papillomavirus (HPV) than previously reported, according to a ... Biomarkers & Prevention. ,Although doctors have known ... womb can harbor multiple HPV types, this study is ...
... Researchers in the Newcastle University at New South Wales central ... chlamydia and they have received financial// support from the vaccine ... they have developed techniques to immunise animals against the infection. ... researchers are working very hard for the past seven years ...
... U.S. Food and Drug Administration (FDA), along with Publix ... warning against allergen in Publix brand// Chocolate Chip Cookie ... director of media and community relations, "The chocolate ... precaution, we are recalling the product. There have been ...
... A 20-year study of women in the Nurses' Health Study ... open angle glaucoma (POAG), the most common form of glaucoma//, ... study is published in the July issue of the journal ... Infirmary, Brigham and Women's ,Hospital, Harvard School of Public Health ...
... that Statin drugs used to reduce the levels of ... of HDL can cause serious muscle// damage. ... such as Lipitor, Pravachol, Zocor, Crestor and Mevacor to ... damage on patient safety information sheets. ,Statin ...
Cached Medicine News:Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3Health News:Type 2 Diabetes Increases the Risk of Glaucoma in Women 2
(Date:12/24/2014)... 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese ... (API) released unaudited preliminary financial results for the ... Fiscal Year 2015 Ended September 30, 2014 Financial ... with $14.7 million in 1Q14 with gross margins ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... SAN DIEGO, March 20, 2012  HUYA Bioscience International ... of China,s preeminent pharmacological researchers, Prof. Deyong Ye ... an international leader in supporting the global development ... Fudan University will focus on specific innovations coming ...
... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Ibandronate Sodium Tablets, 150mg. This product is the generic ... treatment and prevention of osteoporosis in postmenopausal women. ...
Cached Medicine Technology:HUYA Bioscience Announces New Partnership with a High Profile Pharmaceutical Lab at Shanghai's Prestigious Fudan University 2HUYA Bioscience Announces New Partnership with a High Profile Pharmaceutical Lab at Shanghai's Prestigious Fudan University 3
... laboratories that have decided to change to the ... the RELISA ANAs correlation with IFA and many ... competition. While no ELISA ANA currently on the ... our RELISA ANA screen has been shown to ...
... HEp-2 cell line that has been genetically ... autoantibodies, without affecting the other ANA patterns ... worldwide on the HEp-2000 ANA substrate, which ... used in place of standard HEp-2 cells ...
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
... Indirect Fluorescence Assay (IFA) for Anti-native ... for the qualitative and semi-quantitative detection ... nDNA in human serum. Detection of ... be used as an aid in ...
Medicine Products: